Microbiome profiling reveals gut bacterial species associated with rapid lung function decline in people with HIV
- PMID: 40557154
- PMCID: PMC12185991
- DOI: 10.3389/fimmu.2025.1555441
Microbiome profiling reveals gut bacterial species associated with rapid lung function decline in people with HIV
Abstract
Background: People with HIV (PWH) have an increased risk of pulmonary comorbidities compared to people without HIV. The gut microbiome regulates host immunity and is altered in PWH. This study aims to determine potential associations between gut microbiome, lung function decline, and airflow limitation in PWH.
Methods: PWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) Study with available lung function testing and microbiome data were included (n=385). The gut microbiome was characterized using shotgun metagenomic sequencing. Associations between gut microbiome, rapid lung function decline, and airflow limitation were analysed in multivariable logistic regressions adjusted for traditional and HIV-associated risk factors for lung disease.
Results: Several bacterial species were significantly enriched in PWH with rapid lung function decline, including opportunistic pathogenic bacterial species Bacteroides coprophilus, Klebsiella michiganensis, and Clostridium perfringens. A gut microbial dysbiosis index based on compositional changes was associated with rapid lung function decline (adjusted odds ratio (aOR) 1.18, 95% confidence interval (CI) [1.11-1.27], p<0.001), and airflow limitation (aOR 1.16, 95% CI [1.04-1.29], p=0.007) in adjusted multivariable logistic regression analyses.
Conclusion: Associations between the gut dysbiosis index and rapid lung function decline and airflow limitation suggest a potential role of certain gut bacterial species in the pathogenesis of pulmonary comorbidities in PWH.
Keywords: HIV; airflow limitation; gut microbiome; lung function decline; pulmonary comorbidity; spirometry.
Copyright © 2025 Bai, Raju, Knudsen, Thudium, Arentoft, Gelpi, Heidari, Kunisaki, Kristiansen, Hov, Nielsen and Trøseid.
Conflict of interest statement
AK reports grants from the European Commission EU 7th Framework Grant ID:603266, Gilead Sciences Research Scholars Program 2023 and a speaker’s fee from GlaxoSmithKline’; his wife is employed at Novo Nordisk. RT reports a travel grant from Gilead Sciences. NA reports PhD grant from the Research Foundation of Odense University Hospital and Copenhagen University Hospital Rigshospitalet. S-LH reports a research-scholar grant from the Novo Nordic Foundation and a travel grant from GlaxoSmithKline. KMK reports personal fees from Nuvaira for Data and Safety Monitoring Board work. SN reports unrestricted research grants from Novo Nordic Foundation, Rigshospitalet Research Foundation, Independent Research Fund Denmark, Svend Andersen Fonden; she is on advisory board for Gilead, Takeda, and GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures

References
-
- Trickey A, Mcginnis K, Gill MJ, Abgrall S, Berenguer J, Wyen C, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. Lancet Hiv. (2024) 11:e176–e85. doi: 10.1016/S2352-3018(23)00272-2 - DOI - PMC - PubMed
-
- Verboeket SO, Boyd A, Wit FW, Verheij E, Schim van der Loeff MF, Kootstra N, et al. Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGE(h)IV cohort study. Lancet Healthy Longev. (2021) 2:e202–e11. doi: 10.1016/S2666-7568(21)00033-7 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical